Bold and nimble, Boston Oncology is an innovative biogenerics company redefining excellence in the licensing and local development, manufacturing and distribution of US- quality medicines – across therapeutic areas. From our nerve center in Riyadh, we leverage the expertise, daring creativity, and unwavering determination of our international leadership team to provide customers with end-to-end, efficient, single-point-of-contact access to our diverse portfolio of world-class biogenerics. We do this because lives depend on it.
$35M sweet spot round size
2005
$35M
from 1 investors over 1 rounds
Boston Oncology raised $35M on July 26, 2024
Investors: TVM Capital Healthcare